INVA - Innoviva Inc Stock Price, Fair Value and News

15.980.00 (0.00%)Market Closed

Market Summary

15.980.00

Market Closed

0.00%

INVA Stock Price

View Fullscreen

INVA RSI Chart

INVA Valuation

Market Cap

997.9M

Price/Earnings (Trailing)

5.5

Price/Sales (Trailing)

3.21

EV/EBITDA

5.79

Price/Free Cashflow

6.56

INVA Price/Sales (Trailing)

INVA Profitability

EBT Margin

63.80%

Return on Equity

25.78%

Return on Assets

14.31%

Free Cashflow Yield

15.24%

INVA Fundamentals

INVA Revenue

Revenue (TTM)

310.5M

Rev. Growth (Yr)

16.91%

Rev. Growth (Qtr)

-9.72%

INVA Earnings

Earnings (TTM)

181.4M

Earnings Growth (Yr)

4.78%

Earnings Growth (Qtr)

-40.63%

Breaking Down INVA Revenue

Last 7 days

2.4%

Last 30 days

10.4%

Last 90 days

0.8%

Trailing 12 Months

21.1%

How does INVA drawdown profile look like?

INVA Financial Health

Current Ratio

10.42

Debt/Equity

0.63

Debt/Cashflow

0.34

INVA Investor Care

Buy Backs (1Y)

4.67%

Diluted EPS (TTM)

2.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	326.1M	320.9M	315.7M	310.5M
2022	376.7M	361.6M	346.5M	331.3M
2021	350.6M	364.3M	378.1M	391.9M
2020	284.5M	299.4M	322.3M	336.8M
2019	263.8M	260.8M	264.9M	261.0M
2018	229.1M	237.6M	250.7M	261.0M
2017	149.9M	176.0M	191.3M	217.2M
2016	71.2M	93.0M	112.8M	133.6M
2015	16.1M	25.8M	38.4M	53.9M
2014	5.5M	6.5M	7.5M	8.4M
2013	5.3M	5.1M	4.8M	4.5M
2012	145.3M	140.3M	135.3M	5.6M
2011	24.3M	24.4M	24.4M	24.5M
2010	0	0	0	24.2M
2009	0	0	0	24.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Innoviva Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	ronsheim matthew	acquired	189,988	14.88	12,768	see remarks
Mar 05, 2024	basso stephen	acquired	179,988	14.88	12,096	chief financial officer
Mar 05, 2024	zhen marianne	acquired	159,990	14.88	10,752	chief accounting officer
Feb 20, 2024	ronsheim matthew	sold (taxes)	-12,750	15.8	-807	see remarks
Feb 20, 2024	zhen marianne	sold (taxes)	-45,219	15.8	-2,862	chief accounting officer
Jan 18, 2024	ronsheim matthew	sold (taxes)	-25,680	16.05	-1,600	see remarks
Nov 20, 2023	zhen marianne	sold (taxes)	-10,678	13.62	-784	chief accounting officer
Nov 15, 2023	zhen marianne	acquired	-	-	302	chief accounting officer
Nov 15, 2023	zhen marianne	sold	-153,810	13.9903	-10,994	chief accounting officer
Aug 18, 2023	zhen marianne	sold (taxes)	-10,707	13.64	-785	chief accounting officer

Which funds bought or sold INVA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Redwood Investment Management, LLC	added	6.44	36,000	3,254,000	0.31%
May 16, 2024	COMERICA BANK	reduced	-29.6	-1,388,920	2,806,320	0.01%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-8.29	-129,901	880,186	-%
May 16, 2024	JANE STREET GROUP, LLC	added	1,058	2,386,030	2,624,530	-%
May 16, 2024	Ancora Advisors LLC	new	-	3,673	3,673	-%
May 16, 2024	Virtus Investment Advisers, Inc.	reduced	-43.13	-239,326	281,300	0.20%
May 15, 2024	MERCER GLOBAL ADVISORS INC /ADV	added	21.51	48,000	358,000	-%
May 15, 2024	Aquatic Capital Management LLC	new	-	409,956	409,956	0.01%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	new	-	137,697	137,697	0.04%
May 15, 2024	DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	reduced	-38.61	-67,516	94,488	-%

Are Funds Buying or Selling INVA?

Are funds buying INVA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INVA

No. of Funds

Unveiling Innoviva Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	franklin resources inc	10.2%	6,412,700	SC 13G
May 08, 2024	franklin resources inc	10.2%	6,412,700	SC 13D
Feb 14, 2024	putnam investments llc	9.8%	6,270,413	SC 13G/A
Feb 13, 2024	renaissance technologies llc	6.47%	4,144,447	SC 13G/A
Feb 13, 2024	vanguard group inc	10.47%	6,712,443	SC 13G/A
Feb 09, 2024	dimensional fund advisors lp	7.0%	4,516,999	SC 13G
Jan 22, 2024	blackrock inc.	16.1%	10,349,116	SC 13G/A
May 15, 2023	sarissa capital management lp	10.54%	6,904,000	SC 13D/A
Feb 14, 2023	putnam investments llc	7.6%	5,329,107	SC 13G
Feb 13, 2023	renaissance technologies llc	6.06%	4,229,607	SC 13G/A

Recent SEC filings of Innoviva Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	8-K	Current Report
May 13, 2024	SC 13G	Major Ownership Report
May 09, 2024	ARS	ARS
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 08, 2024	SC 13D	13D - Major Acquisition
May 01, 2024	3	Insider Trading
Apr 30, 2024	8-K	Current Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A

Peers (Alternatives to Innoviva Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Innoviva Inc News

Latest updates

Innoviva Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-9.7%	77.00	86.00	67.00	67.00	66.00	66.00	67.00	81.00	94.00	108	98.00	95.00	93.00	90.00	89.00	79.00	79.00	76.00	66.00	64.00	55.00
Costs and Expenses	31.4%	32.00	25.00	-18.69	75.00	35.00	130	-219	88.00	45.00	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-219	26.00	12.00	77.00	-25.31	4.00	6.00	6.00	4.00	3.00	3.00	2.00	5.00	4.00	3.00
S&GA Expenses	15.5%	30.00	26.00	29.00	24.00	20.00	17.00	28.00	12.00	6.00	3.00	3.00	4.00	6.00	5.00	3.00	3.00	3.00	2.00	5.00	4.00	3.00
R&D Expenses	64.6%	4.00	2.00	4.00	15.00	13.00	10.00	12.00	14.00	6.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	-	-	-	-	-
EBITDA Margin	2.5%	0.70*	0.69*	0.32*	0.94*	0.97*	0.96*	1.27*	0.76*	1.04*	1.22*	1.35*	1.21*	-	-	-	-	-	-	-	-	-
Interest Expenses	-1.7%	6.00	6.00	4.00	4.00	4.00	4.00	5.00	4.00	3.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Income Taxes	2860.8%	9.00	-0.31	4.00	5.00	6.00	4.00	57.00	-0.90	7.00	11.00	21.00	25.00	20.00	16.00	9.00	20.00	16.00	12.00	11.00	10.00	9.00
Earnings Before Taxes	-26.3%	45.00	61.00	86.00	6.00	41.00	-64.69	286	20.00	45.00	56.00	123	136	129	91.00	50.00	118	95.00	70.00	58.00	56.00	49.00
EBT Margin	2.1%	0.64*	0.63*	0.22*	0.84*	0.87*	0.87*	1.18*	0.68*	0.96*	1.14*	1.27*	1.12*	-	-	-	-	-	-	-	-	-
Net Income	-40.6%	37.00	62.00	82.00	1.00	35.00	-10.31	229	21.00	38.00	-6.05	103	111	110	-6.62	42.00	98.00	79.00	58.00	47.00	46.00	40.00
Net Income Margin	0.9%	0.58*	0.58*	0.34*	0.80*	0.84*	0.84*	-0.09*	0.88*	0.84*	0.81*	0.84*	0.70*	-	-	-	-	-	-	-	-	-
Free Cashflow	11.9%	37.00	33.00	44.00	38.00	26.00	9.00	16.00	79.00	98.00	98.00	97.00	85.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	1.9%	1,268	1,244	1,188	1,118	1,130	1,231	1,328	1,138	1,107	926	887	789	1,088	1,000	922	880	788	725	676	642	590
Current Assets	-9.6%	311	344	305	324	296	444	33.00	400	318	314	50.00	148	373	342	17.00	500	467	431	367	318	252
Cash Equivalents	-7.8%	178	194	180	173	144	291	301	284	217	202	135	43.00	283	246	479	413	352	278	173	142	65.00
Inventory	-8.1%	37.00	41.00	41.00	47.00	50.00	56.00	71.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-32.9%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0.0%	18.00	18.00	18.00	15.00	28.00	27.00	16.00	6.00	6.00	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	-21.6%	30.00	38.00	36.00	39.00	38.00	135	7.00	126	109	6.00	9.00	5.00	4.00	6.00	7.00	5.00	3.00	5.00	3.00	7.00	4.00
Long Term Debt	0.1%	447	446	446	445	445	444	444	443	443	395	392	390	388	386	383	381	379	377	389	387	385
LT Debt, Current	-	-	-	-	-	-	96.00	96.00	96.00	96.00	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	446	446	445	445	444	444	443	443	395	392	390	388	386	383	381	379	377	389	387	385
Shareholder's Equity	4.3%	704	675	627	555	561	566	641	565	552	526	492	394	697	608	535	493	406	342	284	247	200
Retained Earnings	145.0%	11.00	-25.19	-86.72	-168	-170	-204	-136	-402	-403	-456	-466	-538	-627	-722	-775	-804	-880	-946	-992	-1,032	-1,069
Additional Paid-In Capital	-0.7%	1,086	1,093	1,107	1,117	1,125	1,164	1,171	1,184	1,183	1,264	1,262	1,262	1,261	1,261	1,260	1,260	1,259	1,259	1,258	1,258	1,257
Shares Outstanding	-0.8%	63.00	63.00	64.00	65.00	66.00	69.00	70.00	70.00	70.00	82.00	86.00	95.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	177	166	111	89.00	64.00	62.00	68.00	49.00	36.00	26.00	29.00	17.00	20.00	12.00
Float	-	-	-	-	731,927	-	-	-	924	-	-	-	840,847	-	-	-	877	-	-	-	1,006	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	11.4%	37,047	33,256	43,942	38,182	25,684	8,899	15,690	79,035	98,102	98,381	96,711	84,614	84,107	85,280	74,558	79,794	73,481	66,905	57,402	56,496	76,655
Share Based Compensation	13.9%	1,455	1,277	1,442	1,520	1,598	1,326	3,717	1,350	954	554	542	470	451	447	441	375	435	488	489	474	605
Cashflow From Investing	-735.5%	-43,038	-5,151	-25,888	-	-35,722	-8,678	97,722	-2,522	-143,156	-19,905	-	90,021	-26,394	-315,481	-8,500	-7,000	16,044	51,994	-15,937	20,107	-74,167
Cashflow From Financing	37.2%	-9,165	-14,589	-11,082	-9,206	-136,962	-10,001	-96,163	-9,735	60,331	-12,066	-4,861	-414,260	-21,310	-2,505	-12.00	-11,628	-15,640	-13,749	-10,471	198	246
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	8.00
Buy Backs	-34.6%	9,569	14,636	11,071	9,286	40,735	8,503	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INVA Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 77,499	$ 76,372
Expenses:
Selling, general and administrative	30,405	19,735
Research and development	3,878	12,588
Amortization of acquired intangible assets	6,440	3,805
Changes in fair values of equity method investments, net	(35,342)	(15,817)
Changes in fair values of equity and long-term investments, net	13,335	2,164
Interest and dividend income	(4,399)	(3,365)
Interest expense	5,851	4,427
Other expense, net	1,236	1,346
Total expenses, net	32,375	35,232
Income before income taxes	45,124	41,140
Income tax expense, net	8,592	6,275
Net income and comprehensive income	$ 36,532	$ 34,865
Net income per share:
Basic	$ 0.58	$ 0.51
Diluted	$ 0.46	$ 0.42
Shares used to compute net income per share:
Basic	63,185	67,786
Diluted	84,531	89,788
Royalty revenue
Revenue:
Total revenue	$ 58,415	$ 56,858
Net product sales
Revenue:
Total revenue	19,084	11,514
Expenses:
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)	10,971	8,749
License revenue
Revenue:
Total revenue	0	8,000
License
Expenses:
Cost of license revenue	$ 0	$ 1,600

INVA Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 178,357	$ 193,513
Accounts receivable	14,139	14,454
Receivables from collaboration arrangement	61,871	69,621
Inventory	37,437	40,737
Prepaid expenses	16,551	21,630
Other current assets	2,987	4,264
Total current assets	311,342	344,219
Property and equipment, net	324	483
Equity method investments	151,888	116,546
Equity and long-term investments	476,549	444,432
Capitalized fees paid, net	80,328	83,784
Right-of-use assets	2,269	2,536
Goodwill	17,905	17,905
Intangible assets	223,895	230,335
Other assets	3,112	3,267
Total assets	1,267,612	1,243,507
Current liabilities:
Accounts payable	890	6,717
Accrued personnel-related expenses	3,422	7,020
Accrued interest payable	833	3,422
Deferred revenue	987	1,277
Other accrued liabilities	23,747	19,698
Total current liabilities	29,879	38,134
Long-term debt, net of discount and issuance costs	446,759	446,234
Other long-term liabilities	71,686	71,870
Deferred tax liabilities, net	3,807	563
Income tax payable, long-term	11,800	11,751
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding	0	0
Common stock: $0.01 par value, 200,000 shares authorized, 62,797 and 63,307 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	628	633
Treasury stock: at cost, 32,005 shares as of March 31, 2024 and December 31, 2023	(393,829)	(393,829)
Additional paid-in capital	1,085,539	1,093,340
Retained earnings (accumulated deficit)	11,343	(25,189)
Total stockholders' equity	703,681	674,955
Total liabilities and stockholders' equity	$ 1,267,612	$ 1,243,507

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

WEBSITE	inva.com
INDUSTRY	Biotechnology
EMPLOYEES	101

Innoviva Inc Frequently Asked Questions

What is the ticker symbol for Innoviva Inc? What does INVA stand for in stocks?

INVA is the stock ticker symbol of Innoviva Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Innoviva Inc (INVA)?

As of Fri May 17 2024, market cap of Innoviva Inc is 997.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INVA stock?

You can check INVA's fair value in chart for subscribers.

What is the fair value of INVA stock?

You can check INVA's fair value in chart for subscribers. The fair value of Innoviva Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Innoviva Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INVA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Innoviva Inc a good stock to buy?

The fair value guage provides a quick view whether INVA is over valued or under valued. Whether Innoviva Inc is cheap or expensive depends on the assumptions which impact Innoviva Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INVA.

What is Innoviva Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, INVA's PE ratio (Price to Earnings) is 5.5 and Price to Sales (PS) ratio is 3.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INVA PE ratio will change depending on the future growth rate expectations of investors.